Bispecific anti-IGF-1R and anti-ErbB3 antibodies
US8476409B2 · kind B2 · utility
14Cited by
2References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 19, 2012 |
| Grant date | Jul 2, 2013 |
| Priority date | — |
| Expiry date | Apr 19, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.